Data from patients in ADEPT (Adalimumab Effectiveness in Psoriatic Arthritis Trial) receiving Humira showed that quality of life improved considerably during a 24-week period, using multiple assessment tools. Read the press release. In a standard eight-category questionnaire, patients treated with Humira at week 24 showed clinically significant improvement versus placebo in seven of eight categories:

• physical functioning
• social functioning
• physical role limitations
• bodily pain
• general medical health
• mental health
• vitality

Related Resources:

• The Facts of Humira
• Fast Facts About Psoriatic Arthritis